Abstract 64: Mechanisms of resistance to CDK4/6 inhibitors: Insights from single-cell nucleus sequencing and spatial transcriptomics.

Le résumé fourni par la source

Abstract Breast cancer incidence is increasing worldwide and represents the second most common malignancy in women after lung cancer. Among its subtypes, luminal B accounts for 10-20% of cases and shows a faster proliferation rate. Also, a poorer prognosis than luminal A, with a 5-year survival rate of only 32% at stage 4. Luminal B tumors are characterized by active estrogen receptor signaling and high expression of proliferation-associated genes such as Ki-67 and E2F, leading to enhanced estrogen-driven cell cycle progression. Consequently, CDK4/6 inhibitors, which block the G1 to S phase transition, have shown favorable therapeutic outcomes. However, in a subset of patients, treatment with CDK4/6 inhibitors induces a luminal-to-basal-like phenotypic conversion, which is associated with poor clinical prognosis. To elucidate the mechanism underlying this phenotype, we performed single-nucleus RNA sequencing and spatial transcriptomic analyses on paired pre- and post-treatment tumor biopsies from three patients who exhibited poor responses to CDK4/6 inhibition. After UMAP projection and batch correction, cell type annotation revealed no major changes in the overall cellular composition, with epithelial/tumor cells remaining dominant. Differential expression analysis showed minimal transcriptional changes in endothelial and fibroblast cells but substantial alterations in tumor/epithelial and immune cell populations. Focusing on immune cells, which displayed the largest number of DEGs, subclustering analysis revealed a marked post-treatment increase in innate lymphoid cells (ILCs), while overall immune cell numbers decreased following treatment. Cell-type-specific DEG analysis further identified substantial transcriptional reprogramming within plasma cells, CD4+, and CD8+ T cells. In parallel, tumor/epithelial cells exhibited distinct subtype redistribution after CDK4/6 inhibition, which is currently under detailed characterization. Spatial transcriptomic mapping based on nucleus-seq-derived cell type signatures is underway to visualize cell-type distribution and microenvironmental remodeling before and after treatment. Collectively, our integrative analyses aim to uncover the mechanisms of CDK4/6 inhibitor resistance, highlighting the potential roles of ILC expansion, immune remodeling, and epithelial plasticity in luminal-to-basal transition, and to identify biomarkers predictive of therapeutic response. Citation Format: Seung-eun Bang, EunChae Kim, Won-Ji Ryu, Hyein Jung, Yoonjin Cha, Joohyuk Sohn, Gun Min Kim, Kyoo Hyun Kim, Byungjin Hwang, Min Hwan Kim. Mechanisms of resistance to CDK4/6 inhibitors: Insights from single-cell nucleus sequencing and spatial transcriptomics [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2026; Part 1 (Regular Abstracts); 2026 Apr 17-22; San Diego, CA. Philadelphia (PA): AACR; Cancer Res 2026;86(7 Suppl):Abstract nr 64.

Ce résumé expose les affirmations des auteurs. BNTIC ne l’interprète pas comme une validation indépendante des résultats.